475 related articles for article (PubMed ID: 15747226)
1. [Longterm therapy of schizophrenia].
Pajonk FG; Wobrock T; Falkai P
Fortschr Neurol Psychiatr; 2005 Mar; 73(3):161-74; quiz 175-7. PubMed ID: 15747226
[No Abstract] [Full Text] [Related]
2. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
Benoit M; Pon J; Zimmermann MA
Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
[No Abstract] [Full Text] [Related]
3. [Longterm therapy of schizophrenia].
Pajonk FG; Wobrock T; Falkai P
Fortschr Neurol Psychiatr; 2005 Apr; 73(4):218-31; quiz 232-4. PubMed ID: 15806439
[No Abstract] [Full Text] [Related]
4. Management of schizophrenia. Long-term clinical studies with special reference to the combination of psychotherapy with depot neuroleptics.
Lindberg D
Acta Psychiatr Scand Suppl; 1981; 289():1-26. PubMed ID: 6110314
[No Abstract] [Full Text] [Related]
5. [Longterm treatment of schizophrenia].
Pajonk VF
MMW Fortschr Med; 2006 Jan; 148(4):35-8. PubMed ID: 16502798
[TBL] [Abstract][Full Text] [Related]
6. Longterm maintenance therapy with depot haloperidol in schizophrenia.
Zbytovský J
Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
[No Abstract] [Full Text] [Related]
7. Depot neuroleptic therapy: clinical considerations.
Remington GJ; Adams ME
Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
[TBL] [Abstract][Full Text] [Related]
8. [Is depot formulation a long-term optimal treatment option?].
Musch A
Med Monatsschr Pharm; 2005 Nov; 28(11):414-6. PubMed ID: 16309031
[No Abstract] [Full Text] [Related]
9. [Treatment of acute and chronic psychoses in childhood and adolescence].
Eggers Ch
MMW Fortschr Med; 2005 Dec; 147(48):41, 43-5. PubMed ID: 16389861
[TBL] [Abstract][Full Text] [Related]
10. Relapse prevention and recovery in the treatment of schizophrenia.
Schooler NR
J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
[TBL] [Abstract][Full Text] [Related]
11. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Hogarty GE
J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
[TBL] [Abstract][Full Text] [Related]
12. [Treatment-resistant schizophrenia - biological treatments].
Hasan A; Wobrock T
Fortschr Neurol Psychiatr; 2013 Aug; 81(8):464-71; quiz 472. PubMed ID: 23939560
[No Abstract] [Full Text] [Related]
13. [Early-stage schizophrenia in cases of committed suicide].
Nakayasu N; Seki Y
Seishin Shinkeigaku Zasshi; 2005; 107(10):1078-85. PubMed ID: 16381391
[No Abstract] [Full Text] [Related]
14. [To increase compliance-knowledge. Only every second schizophrenia patient remains faithful to the therapy].
MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579500
[No Abstract] [Full Text] [Related]
15. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
16. Algorithm for treatment-refractory schizophrenia.
Koshino Y
Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S9-13. PubMed ID: 10560891
[TBL] [Abstract][Full Text] [Related]
17. Drug compliance and cognitive-behavioral therapy in schizophrenia.
Lecompte D
Acta Psychiatr Belg; 1995; 95(2):91-100. PubMed ID: 8525853
[TBL] [Abstract][Full Text] [Related]
18. The case for long-acting antipsychotic agents in the post-CATIE era.
Nasrallah HA
Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
[TBL] [Abstract][Full Text] [Related]
19. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
Chue P
J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
[TBL] [Abstract][Full Text] [Related]
20. How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
Preskorn SH
J Psychiatr Pract; 2008 May; 14(3):170-5. PubMed ID: 18520787
[No Abstract] [Full Text] [Related]
[Next] [New Search]
